drug · small molecule
finerenone
Marketedupdated 3mo agoby Bayer AG🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.
targets
Mineralocorticoid receptor
all catalysts(0)
nothing on the calendar yet
Trials studying finerenone
- phase3A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
- —An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
- —An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
- phase3A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- phase3A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- —An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
- phase3A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- phase3A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 11, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 29, 2035compositionUS RE49826
- Jul 29, 2035compositionUS RE49826
- Jul 29, 2035compositionUS RE49826
- Aug 26, 2033compositionUS 8436180
- Aug 26, 2033compositionUS 8436180
- Aug 26, 2033compositionUS 8436180
FDA exclusivities (6)
- Jul 11, 2028I-970Indication (3y)1.9y
- Jul 11, 2028I-970Indication (3y)1.9y
- Jul 11, 2028NSNS1.9y
- Jul 9, 2026NCENew Chemical Entity (5y)
- Jul 9, 2026NCENew Chemical Entity (5y)
- Jul 9, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that